In a nutshell This study investigated the impact of watchful waiting on the outcomes of patients with follicular lymphoma (FL). This study concluded that these patients had a higher risk of disease transformation compared to patients who receive immediate treatment. Some background About 15 – 30% of patients with FL have advanced-stage (stage 3...
Read More
In a nutshell This article provided recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL). Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL). It accounts for about 30% of new NHL cases in the U.S. Current treatments are effective in 60 – 70% of patients....
Read More
In a nutshell This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of...
Read More
In a nutshell This study investigated the effectiveness and safety of brentuximab vedotin (Adcetris) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that brentuximab vedotin was effective and well-tolerated in these high-risk patients. Some background The...
Read More
In a nutshell This article reviewed the use of proton therapy in adult patients with lymphoma in the mediastinum (the middle section of the chest around the lungs). Some background Many lymphomas are found in the mediastinum, next to the heart, lungs, and breasts. These organs are especially sensitive to chemotherapy and radiation therapy. In adult...
Read More
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read MoreIn a nutshell This study is investigating the effectiveness of T-cell immunotherapy in Hodgkin’s lymphoma (HL) patients with tumors that are EBV+ (positive for Epstein-Barr virus). This study is recruiting in Duart, California, Washington, D.C., Baltimore, New York, Pittsburgh, and Houston. The details It is thought that individuals who have...
Read More
In a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...
Read More
In a nutshell This article reviewed the effectiveness and safety of CAR T-cell therapy in patients with non-Hodgkin’s lymphoma. Some background The standard treatment for non-Hodgkin’s lymphoma (NHL) is chemotherapy plus immunotherapy. Patients with high-risk disease tend to become refractory (do not respond to treatment). For these...
Read More
In a nutshell This study investigated the outcomes of umbilical cord blood transplantation in pretreated patients with Hodgkin’s lymphoma. The authors concluded that this procedure is a feasible treatment option for these patients. Some background Patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma have...
Read More
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read More
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read More
